Corbus Pharmaceuticals Holdings Inc (CRBP) Stock: What Does the Chart Say Thursday?

Corbus Pharmaceuticals Holdings Inc (CRBP) stock is up 28.57% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Corbus Pharmaceuticals Holdings Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CRBP!

See Full CRBP Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CRBP Stock Today?

Corbus Pharmaceuticals Holdings Inc (CRBP) stock is trading at $0.18 as of 1:56 PM on Thursday, Feb 2, an increase of $0.01, or 6.83% from the previous closing price of $0.16. The stock has traded between $0.17 and $0.19 so far today. Volume today is high. So far 5,919,544 shares have traded compared to average volume of 1,395,779 shares.

More About Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune system. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Click Here to get the full Stock Report for Corbus Pharmaceuticals Holdings Inc stock.